Friel Lab
News & Impact

You are here

Cumulative Efficacy of Longitudinal Repeat Salivary Gland OnabotulinumtoxinA Injection: A Retrospective Study

Journal Article
Hannah Shoval, Kathleen Friel, Jared Levin, Heakyung Kim
Year Published: 
Am J Phys Med Rehabil . 2021 Aug 1;100(8):798-802. doi: 10.1097/PHM.0000000000001675.
PMID: 33394592 | DOI: 10.1097/PHM.0000000000001675
Abstract on PubMed


Aim: We hypothesized that repeat onabotulinumtoxinA (BTX-A) injections to salivary glands would have a cumulative effect on drooling, leading to prolonged efficacy duration.

Methods: We retrospectively reviewed medical records and conducted a telephone survey of individuals treated with BTX-A to the salivary glands to investigate ongoing efficacy or side effects. Outcome measures were duration of decrease in drooling, and adverse events. The main independent variable was the number of injections. We identified 52 consecutive individuals (26 females) with cerebral palsy with an average age of 9 years, 3 month ± 5 years, 2 months who had received BTX-A for sialorrhea.

Results: Linear regression analysis showed that each additional injection resulted in the duration of efficacy being 0.68 months longer (P <0.001, R2=0.47). Age, sex, Gross Motor Function Classification System (GMFCS) level, presence of tube feeding, presence of tracheostomy, gastroesophageal reflex, seizures and concurrent intramuscular injections seizures were not significant contributors to the association between injection number and efficacy duration F (6, 45) = 1.01, p= 0.431. Interpretation there may be a cumulative effect of BTX-A injections to the salivary glands, resulting in longer periods of efficacy with consecutive injection.


Conditions & Recovery

Motor Recovery Icon
Write and walk again.